Dr. Alimohamed is a Medical Oncologist at the Tom Baker Cancer Centre, Calgary, AB as well as a Clinical Associate Professor in the Department of Medicine at the University of Calgary. She is the Program Director for the Medical Oncology Training Program at the University of Calgary. She is involved with all levels of undergraduate, postgraduate, and continuing medical education. Dr. Alimohamed is actively involved in clinical trials in genitourinary and breast malignancies with specific research interests in genitourinary oncology. She sits on the Medical Advisory Board for Bladder Cancer Canada.
Biography
Area of Focus
Summary of Research
KEY PUBLICATIONS:
- Lavoie JM, Sridhar SS, Ong M, North S, Alimohamed N, McLeod D, Eigl BJ. The rapidly evolving landscape of first-line targeted therapy in metastatic urothelial cancer: A systemic review. Oncologist 2021; doi:10.1002/onco.13827, 10.1002/onco.13827
- Alimohamed N, Leibowitz-Amit R, Templeton A, Seah JA, Vera-Badillo F, Joshua AM, Wong SE, Knox JJ, Tannock IF, Sridhar SS. The impact of special access programs (SAP) on prescribing patterns in metastatic castration resistant prostate cancer (mCRPC). Int J of Clin Oncol and Cancer Res. 2021; doi: 10.11648/j.ijcocr.20210601.15.
- Poscente M, Gan CL, Heng DYC, Alimohamed N. Case – Acquired hemophilia A in a patient with metastatic castration-resistant prostate cancer. Can Urol Assoc J. 2021
- Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, Blais N, Sridhar SS. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021;18(2):104-114. doi:10.1038/s41585-020-00404-6
- Black PC, Alimohamed NS, Berman D, Blais N, Eigl B, Karakiewicz PI, Kassouf W, Kulkarni GS, Ong M, Spatz A, Sridhar SS, Stockley T, van der Kwast T, Hew H, Park-Wylie L, North SA. Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Can Urol Assoc J. 2020;14(8):E373-E382. doi:10.5489/cuaj.6458
- Kaiser J, Li H, North SA, Leibowitz-Amit R, Seah JA, Morshed N, Chau C, Lee-Ying R, Heng DYC, Sridhar S, Crabb SJ, Alimohamed NS. The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. Bladder Cancer. 2018 Apr 26;4(2):185-194
- Yip SM, Kaiser J, Li H, North S, Heng DYC, Alimohamed NS. Real-world outcomes in advanced urothelial cancer and the role of the neutrophil to lymphocyte ratio. Clin Genitourin Cancer. 2018 June;16(3):e637-e644.
- Alimohamed N, Sridhar SS. Complete responses with targeted therapy in metastatic renal cell carcinoma: balancing efficacy and toxicity. Eur Urol. 2016 Sep;70(3):476-7.
- Alimohamed N, Sridhar SS. Options in metastatic urothelial cancer after first-line therapy. Curr Opin Support Palliat Care. 2015 Sep;9(3):255-60
Area Of Focus
Summary Of Research
KEY PUBLICATIONS:
- Lavoie JM, Sridhar SS, Ong M, North S, Alimohamed N, McLeod D, Eigl BJ. The rapidly evolving landscape of first-line targeted therapy in metastatic urothelial cancer: A systemic review. Oncologist 2021; doi:10.1002/onco.13827, 10.1002/onco.13827
- Alimohamed N, Leibowitz-Amit R, Templeton A, Seah JA, Vera-Badillo F, Joshua AM, Wong SE, Knox JJ, Tannock IF, Sridhar SS. The impact of special access programs (SAP) on prescribing patterns in metastatic castration resistant prostate cancer (mCRPC). Int J of Clin Oncol and Cancer Res. 2021; doi: 10.11648/j.ijcocr.20210601.15.
- Poscente M, Gan CL, Heng DYC, Alimohamed N. Case – Acquired hemophilia A in a patient with metastatic castration-resistant prostate cancer. Can Urol Assoc J. 2021
- Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, Blais N, Sridhar SS. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021;18(2):104-114. doi:10.1038/s41585-020-00404-6
- Black PC, Alimohamed NS, Berman D, Blais N, Eigl B, Karakiewicz PI, Kassouf W, Kulkarni GS, Ong M, Spatz A, Sridhar SS, Stockley T, van der Kwast T, Hew H, Park-Wylie L, North SA. Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Can Urol Assoc J. 2020;14(8):E373-E382. doi:10.5489/cuaj.6458
- Kaiser J, Li H, North SA, Leibowitz-Amit R, Seah JA, Morshed N, Chau C, Lee-Ying R, Heng DYC, Sridhar S, Crabb SJ, Alimohamed NS. The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. Bladder Cancer. 2018 Apr 26;4(2):185-194
- Yip SM, Kaiser J, Li H, North S, Heng DYC, Alimohamed NS. Real-world outcomes in advanced urothelial cancer and the role of the neutrophil to lymphocyte ratio. Clin Genitourin Cancer. 2018 June;16(3):e637-e644.
- Alimohamed N, Sridhar SS. Complete responses with targeted therapy in metastatic renal cell carcinoma: balancing efficacy and toxicity. Eur Urol. 2016 Sep;70(3):476-7.
- Alimohamed N, Sridhar SS. Options in metastatic urothelial cancer after first-line therapy. Curr Opin Support Palliat Care. 2015 Sep;9(3):255-60